Synthetic DNA manufacturer 4basebio rebrands as part of therapeutic expansion
Cambridge-based 4basebio has launched refreshed branding and a new website following its £40 million investment round, as the AIM-listed company positions itself for growth in synthetic DNA manufacturing for next-generation therapeutics including gene therapy, RNA therapeutics and vaccine development.
4basebio PLC has introduced updated visual identity and digital presence to reflect its expanding capabilities in synthetic DNA manufacturing for clinical applications. The specialist nucleic acids company completed the rebrand following several operational milestones achieved since its substantial funding round in November 2024.
MHRA certification strengthens clinical manufacturing position
The rebrand coincides with significant regulatory progress for the company. In April 2025, 4basebio secured MHRA GMP certification for manufacturing and supplying synthetic DNA for clinical use, marking a crucial milestone in its ability to serve pharmaceutical and biotechnology clients developing advanced genetic therapies.
The certification enables 4basebio to provide GMP-grade synthetic DNA starting materials for companies developing RNA therapeutics, cell and gene therapies, and next-generation vaccines. This regulatory approval positions the company to capture growing demand
for high-quality synthetic DNA in the clinical development pipeline.
Enhanced digital platform supports customer engagement
The company’s redesigned website provides comprehensive information about its manufacturing services across synthetic DNA, mRNA, gene editing technologies, and plasmid-free manufacturing platforms.
A newly developed content hub offers technical resources including data sheets, whitepapers, case studies, and application notes for research and development teams.
“This brand refresh marks an exciting milestone for 4basebio,” said Heikki Lanckriet, CEO of 4basebio. “As we continue to scale our operations and deepen our work with partners across RNA, cell and gene therapy, and vaccine development, we wanted our identity to reflect the sophistication and innovation that define our approach.”
The rebrand supports 4basebio’s commercial strategy of increased industry presence and expanded customer engagement as the synthetic DNA manufacturing sector experiences sustained growth driven by advancing genetic medicine development programmes.
To learn more about 4basebio’s technology platforms, manufacturing services, GMP certification and recent partnerships, visit the new website: www.4basebio.com.
Heikki Lanckriet, CEO, 4basebio
